Study of Amiodarone Given Before Lung Surgery to Prevent Atrial Fibrillation After Lung Resection
Beth Israel Deaconess Medical Center
Atrial fibrillation is a very common complication of pulmonary resection. Patients who
develop atrial fibrillation require additional treatment and are more likely to stay in the
hospital for longer period of time increasing the costs associated with the operation. We
propose a randomized controlled trial to see if oral amiodarone given for one week before
surgery can prevent atrial fibrillation after pulmonary resection. We plan to evaluate the
incidence of atrial fibrillation in patients who received preoperative amiodarone and compare
them to the incidence of atrial fibrillation in patients who did not received preoperative
High Intensity Focused Ultrasound (HIFU) Ablation System Study
The purpose of this study is to determine if the HIFU Pulmonary Vein Ablation System is
effective in the treatment of paroxysmal Atrial Fibrillation compared to the control of best
medical therapy with FDA approved antiarrhythmic drugs.
Amiodarone for the Prevention of Reperfusion Ventricular Fibrillation
This was a prospective, randomized, double blinded study in which patients undergoing a
cardiopulmonary bypass (CPB) with aortic cross clamping were randomly assigned to receive
amiodarone, lidocaine, or saline placebo prior to removal of the aortic cross clamp. (CPB is
a technique that temporarily takes over the function of the heart and lungs during surgery,
maintaining the circulation of blood and the oxygen content of the body.) Specifically, we
will test the hypothesis that amiodarone is superior to both lidocaine and placebo in the
prevention of a severely abnormal heart rhythm when the blood flow is restored to the heart
after the aortic cross clamp is removed.
AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study
The purpose of this study is to determine whether early atrioventricular node (AVN) ablation
with pacing device therapy will reduce death and hospitalization when compared to the
conventional drug therapy in elderly patients with recurrent and symptomatic atrial
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.